Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 541 to 543 of 543 entries
Sorted by: Best Match Show Resources per page
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis.

Clinical kidney journal

Sinha S, Gould LJ, Nigwekar SU, Serena TE, Brandenburg V, Moe SM, Aronoff G, Chatoth DK, Hymes JL, Miller S, Padgett C, Carroll KJ, Perelló J, Gold A, Chertow GM.
PMID: 35035944
Clin Kidney J. 2021 Jul 06;15(1):136-144. doi: 10.1093/ckj/sfab117. eCollection 2022 Jan.

BACKGROUND: Calcific uraemic arteriolopathy (CUA; calciphylaxis) is a rare disease seen predominantly in patients receiving dialysis. Calciphylaxis is characterized by poorly healing or non-healing wounds, and is associated with mortality, substantial morbidity related to infection and typically severe pain....

Cite
Sinha S, Gould LJ, Nigwekar SU, et al. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clin Kidney J. 2021;15(1):136-144doi: 10.1093/ckj/sfab117.
Sinha, S., Gould, L. J., Nigwekar, S. U., Serena, T. E., Brandenburg, V., Moe, S. M., Aronoff, G., Chatoth, D. K., Hymes, J. L., Miller, S., Padgett, C., Carroll, K. J., Perelló, J., Gold, A., & Chertow, G. M. (2022). The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clinical kidney journal, 15(1), 136-144. https://doi.org/10.1093/ckj/sfab117
Sinha, Smeeta, et al. "The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis." Clinical kidney journal vol. 15,1 (2022): 136-144. doi: https://doi.org/10.1093/ckj/sfab117
Sinha S, Gould LJ, Nigwekar SU, Serena TE, Brandenburg V, Moe SM, Aronoff G, Chatoth DK, Hymes JL, Miller S, Padgett C, Carroll KJ, Perelló J, Gold A, Chertow GM. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clin Kidney J. 2021 Jul 06;15(1):136-144. doi: 10.1093/ckj/sfab117. eCollection 2022 Jan. PMID: 35035944; PMCID: PMC8757410.
Copy Download .nbib Format: NLM
Challenges for large scale simulation: general discussion.

Faraday discussions

Brandenburg JG, Burke K, Civalleri B, Cole DJ, Csányi G, David G, Gidopoulos NI, Gowland D, Helgaker T, Herbst MF, Hourahine B, Irons TJP, Jacob CR, Loos PF, Mehta N, Mulay MR, Neugebauer J, Pernal K, Pribram-Jones A, Romaniello P, Ryder MR, Savin A, Sirbu D, Skylaris CK, Truhlar DG, Wetherell J, Yang W.
PMID: 33227116
Faraday Discuss. 2020 Dec 04;224:309-332. doi: 10.1039/D0FD90024A.

No abstract available.

Cite
Brandenburg JG, Burke K, Civalleri B, et al. Challenges for large scale simulation: general discussion. Faraday Discuss. 2020;224:309-332doi: 10.1039/D0FD90024A.
Brandenburg, J. G., Burke, K., Civalleri, B., Cole, D. J., Csányi, G., David, G., Gidopoulos, N. I., Gowland, D., Helgaker, T., Herbst, M. F., Hourahine, B., Irons, T. J. P., Jacob, C. R., Loos, P. F., Mehta, N., Mulay, M. R., Neugebauer, J., Pernal, K., Pribram-Jones, A., Romaniello, P., Ryder, M. R., Savin, A., Sirbu, D., Skylaris, C. K., Truhlar, D. G., Wetherell, J., & Yang, W. (2020). Challenges for large scale simulation: general discussion. Faraday discussions, 224309-332. https://doi.org/10.1039/D0FD90024A
Brandenburg, Jan Gerit, et al. "Challenges for large scale simulation: general discussion." Faraday discussions vol. 224 (2020): 309-332. doi: https://doi.org/10.1039/D0FD90024A
Brandenburg JG, Burke K, Civalleri B, Cole DJ, Csányi G, David G, Gidopoulos NI, Gowland D, Helgaker T, Herbst MF, Hourahine B, Irons TJP, Jacob CR, Loos PF, Mehta N, Mulay MR, Neugebauer J, Pernal K, Pribram-Jones A, Romaniello P, Ryder MR, Savin A, Sirbu D, Skylaris CK, Truhlar DG, Wetherell J, Yang W. Challenges for large scale simulation: general discussion. Faraday Discuss. 2020 Dec 04;224:309-332. doi: 10.1039/D0FD90024A. PMID: 33227116.
Copy Download .nbib Format: NLM
[Care for mental well-being of cancer patients: Support during and after primary treatment].

Nederlands tijdschrift voor geneeskunde

Dekker J, Brandenbarg D, Verheul HMW.
PMID: 34346647
Ned Tijdschr Geneeskd. 2021 Jul 08;165.

Cancer is associated with sometimes strong emotions. However, emotions are mostly adaptive - they help people adapt to cancer. Adaptive emotions do not need to be treated; instead, emotional support is key. Professional mental health care is indicated only...

Cite
Dekker J, Brandenbarg D, Verheul HMW. Zorg voor mentaal welbevinden bij patiënt met kanker. [Care for mental well-being of cancer patients: Support during and after primary treatment]. Ned Tijdschr Geneeskd. 2021;165
Dekker, J., Brandenbarg, D., & Verheul, H. M. W. (2021). Zorg voor mentaal welbevinden bij patiënt met kanker. [Care for mental well-being of cancer patients: Support during and after primary treatment]. Nederlands tijdschrift voor geneeskunde, 165.
Dekker, Joost, et al. "Zorg voor mentaal welbevinden bij patiënt met kanker." [Care for mental well-being of cancer patients: Support during and after primary treatment]. Nederlands tijdschrift voor geneeskunde vol. 165 (2021).
Dekker J, Brandenbarg D, Verheul HMW. Zorg voor mentaal welbevinden bij patiënt met kanker. [Care for mental well-being of cancer patients: Support during and after primary treatment]. Ned Tijdschr Geneeskd. 2021 Jul 08;165. Dutch. PMID: 34346647.
Copy Download .nbib Format: NLM
Showing 541 to 543 of 543 entries